Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Could Seize Share From Sanofi - Analysts

 
• By Andrew McConaghie

Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.

Pregnant woman vaccine
Interim analysis of the Phase IIb study showed 85% efficacy against RSV infection for infants born to vaccinated mothers.

More from Business

More from Scrip